If you haven't heard about Gilead's (NASDAQ:GILD) Sovaldi, the hepatitis c cure, you haven't been paying attention. The whole market is aware of the $2.3 billion wonder drug and the fight over its cost.
But Sovaldi isn't Gilead's only wonder drug. There is another -- one which the WHO and CDC recommend people take to help prevent HIV. It's the lynchpin of New York's plan to try and reduce new HIV incidence to the level of tuberculosis by 2020.
Watch the video below to learn more about this incredible opportunity for Gilead investors.
Leaked: This could be even bigger than Gilead's opportunity
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. The Motley Fool owns shares of Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.